Skip to main content
. 2023 Sep 25;623(7987):594–600. doi: 10.1038/s41586-023-06649-6

Extended Data Fig. 3. Distribution of major SARS-CoV-2 variants between placebo and molnupiravir treatments in the AGILE trial dataset.

Extended Data Fig. 3

The proportion of patients infected with each variant is shown. The proportions are similar suggesting that differences between placebo and molnupiravir spectra will not be influenced by previously observed spectrum differences between variants (Ruis et al., Bloom et al.). VOC = variant of concern.